Success Metrics

Clinical Success Rate
37.5%

Based on 3 completed trials

Completion Rate
38%(3/8)
Active Trials
10(36%)
Results Posted
33%(1 trials)
Terminated
5(18%)

Phase Distribution

Ph phase_1
13
46%
Ph phase_2
9
32%
Ph phase_3
3
11%
Ph not_applicable
2
7%

Phase Distribution

13

Early Stage

9

Mid Stage

3

Late Stage

Phase Distribution27 total trials
Phase 1Safety & dosage
13(48.1%)
Phase 2Efficacy & side effects
9(33.3%)
Phase 3Large-scale testing
3(11.1%)
N/ANon-phased studies
2(7.4%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

37.5%

3 of 8 finished

Non-Completion Rate

62.5%

5 ended early

Currently Active

10

trials recruiting

Total Trials

28

all time

Status Distribution
Active(13)
Completed(3)
Terminated(5)
Other(7)

Detailed Status

Recruiting10
unknown7
Terminated5
Completed3
Not yet recruiting3

Development Timeline

Analytics

Development Status

Total Trials
28
Active
10
Success Rate
37.5%
Most Advanced
Phase 3

Trials by Phase

Phase 113 (48.1%)
Phase 29 (33.3%)
Phase 33 (11.1%)
N/A2 (7.4%)

Trials by Status

completed311%
terminated518%
not_yet_recruiting311%
recruiting1036%
unknown725%

Recent Activity

Clinical Trials (28)

Showing 20 of 28 trialsScroll for more
NCT07770802Phase 1

Clinical Study of HS-IT101 Injection in the Treatment of Advanced Renal Cancer

Recruiting
NCT07830342Phase 1

A Clinical Study of HS-IT101 Injection in Patients With Advanced Non-Small Cell Lung Cancer

Recruiting
NCT06047171Phase 2

Rescue of Nephrons With ALE.F02 (RENAL-F02)

Recruiting
NCT07712588Phase 2

Birelentinib Plus R-CHOP in Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma (TAI-SHAN19)

Not Yet Recruiting
NCT05634785Phase 2

CD30 CAR for CD30+ NSGCT

Completed
NCT07255664Phase 1

A FIH, Phase I/IIa, Trial Assessing Feasibility of Administrations of TIL-based Immunotherapy in Patients With Metastatic CRC and PC

Recruiting
NCT07493538Phase 2

MT2025-35 Allogeneic Hematopoietic Stem Cell Transplantation Using Reduced Intensity Conditioning Treosulfan and Fludarabine, With Post-Transplant Cytoxan (PTCy) for the Treatment of Hematological Diseases

Recruiting
NCT05987696Phase 1

Natural Killer(NK) Cell Therapy in Acute Myeloid Leukemia

Completed
NCT04611126Phase 1

T-cell Therapy in Combination With Nivolumab, Relatlimab and Ipilimumab for Patients With Metastatic Ovarian Cancer

Terminated
NCT04221035Phase 3

High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN)

Recruiting
NCT06108739Phase 3

ATG Plus Low-dose PT-Cy for GVHD Prevention

Terminated
NCT06532812Phase 1

TIL Gean Therapy Combined With Immunotherapy for Advanced or Metastatic Refractory Breast Cancer

Recruiting
NCT06532799Phase 1

TIL Therapy Combined With Pembrolizumab for Advanced or Metastatic Refractory Stomach and Esophageal Cancer

Recruiting
NCT05601466Phase 1

Natural Killer(NK) Cell Therapy for Acute Myeloid Leukemia

Terminated
NCT05601830Phase 1

Natural Killer(NK) Cell Therapy for AML Minimal Residual Disease

Terminated
NCT04943757Phase 2

Post-transplantation Benadamustine and Cyclophosphamide in Patients With Refractory Myeloid Malignancies

Completed
NCT06238245Phase 2

Combination of ATG-based Conditioning Regimen and PTCy for GVHD Prevention in Allo-HSCT After PD-1 Blockade

Not Yet Recruiting
NCT05990985Not Applicable

The Efficacy and Safety of the RCMOP Sequential Therapy as a First-line Treatment for Patients With Intermediate-to-high Risk Diffuse Large B-cell Lymphoma Who Had Incomplete Remission.

Not Yet Recruiting
NCT04706936Phase 1

Novel BCMA-targeted CAR-T Cell Therapy for Multiple Myeloma

Unknown
NCT05432531Phase 3

Efficiency of Use of Baracetinib in Treatment of Lupus Nephritis

Unknown

Drug Details

Intervention Type
DRUG
Total Trials
28